Blog
RSS FeedPosted by Michael Wonder on 15 Jul 2025
Vertex announces broad reimbursement agreement with NHS England for Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) an innovative once daily CFTR modulator for the treatment of cystic fibrosis
14 July 2025 - All eligible people with cystic fibrosis in England can now benefit from this medicine - ...
Posted by Michael Wonder on 24 Jun 2025
Australians with cystic fibrosis benefit from life changing expanded listing
24 June 2025 - More Australians living with cystic fibrosis will have affordable access to a life changing treatment option ...
Posted by Michael Wonder on 23 Jun 2025
‘Barriers lifted’: cystic fibrosis treatment reaches final waiting patients
23 June 2025 - Ex-Wallabies player Nathan Charles has lived with cystic fibrosis for decades. ...
Posted by Michael Wonder on 14 Dec 2024
Roche Canada and the pan-Canadian Pharmaceutical Alliance successfully complete negotiations for Tecentriq SC (atezolizumab solution for subcutaneous injection)
13 December 2024 - Roche Canada today announced that it successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance for Tecentriq ...
Posted by Michael Wonder on 04 Oct 2024
Netarsudil mesylate with latanoprost for the treatment of patients with primary open-angle glaucoma or ocular hypertension
2 October 2024 - NiCE has published final evidence-based recommendations on the use of netarsudil mesylate with latanoprost (Roclanda) for ...
Posted by Michael Wonder on 02 Oct 2024
Securing supply of PrEP
1 October 2024 - The Australian Government is ensuring thousands of Australians, with or at risk of contracting HIV, are ...
Posted by Michael Wonder on 29 Jul 2024
Life changing medicine for children with cystic fibrosis
29 July 2024 - Australian children with cystic fibrosis now have access to cheaper medicines earlier under the PBS thanks ...
Posted by Michael Wonder on 22 Jun 2024
Vertex announces extended long-term reimbursement agreement with NHS England for access to cystic fibrosis medicines Kaftrio, Symkevi and Orkambi
20 June 2024 - Agreement includes access to any future licence extensions. ...
Posted by Michael Wonder on 11 Jun 2024
Trifluridine with tipiracil hydrochloride in combination with bevacizumab for the treatment of patients with metastatic colorectal cancer after two systemic treatments
6 June 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 02 Apr 2024
Relugolix–estradiol–norethisterone acetate for the treatment of patients with pain associated with endometriosis
28 March 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 08 Feb 2024
Knight Therapeutics announces launch of Bijuva in Canada
6 February 2024 - Knight Therapeutics announced today the launch of Bijuva (oestradiol and progesterone) capsules in Canada. ...
Posted by Michael Wonder on 05 Feb 2024
Sumitomo Pharma and Pfizer Canada announce availability of Myfembree in Canada
31 January 2024 - In partnership with Sumitomo, Pfizer is proud to announce that supply of Myfembree (relugolix 40 mg, estradiol ...
Posted by Michael Wonder on 23 Jan 2024
Remdesivir and the combination of tixagevimab and cilgavimab for the treatment of patients with COVID-19 disease
18 January 2024 - NICE has published additional draft guidance on the use of remdesivir and the combination of tixagevimab ...
Posted by Michael Wonder on 21 Jan 2024
Advanced melanoma treatment to be added to Pharmaceutical Benefits Scheme
21 January 2024 - Treatment for advanced melanoma is set to become cheaper under the Pharmaceutical Benefits Scheme in the ...
Posted by Michael Wonder on 14 Jan 2024
1.4 million more people at risk of severe COVID-19 to have access to antiviral Paxlovid
11 January 2024 - A further 1.4 million people who have an increased risk for progression to severe COVID-19 will be ...